Vanda Pharmaceuticals (VNDA) Net Margin (2010 - 2026)
Vanda Pharmaceuticals (VNDA) posted Net Margin of 93.82% for Q1 2026, up 61.98% sequentially from 246.76% in Q4 2025, and down 3488.0% YoY from 2.77% in Q1 2025.
Vanda Pharmaceuticals (VNDA) Net Margin (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals has reported Net Margin for 17 years, with the latest figure at 93.82% in Q1 2026.
- Quarterly Net Margin fell 3488.0% year-over-year to 93.82% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 109.97% (down 8800.0% YoY) and the FY2025 annual result came in at 102.02%, down 9251.0% from the prior year.
- Net Margin advanced to 93.82% in Q1 2026 per VNDA's latest filing, from 246.76% in the prior quarter.
- Over five years, Net Margin peaked at 10.64% in Q4 2022 and troughed at 246.76% in Q4 2025.
- A 5-year average of 30.41% and a median of 8.95% in 2024 frame the typical range for Net Margin.
- The sharpest annual moves came in 2023 and 2025: Net Margin jumped 1590 bps in 2023, then slumped 23759 bps in 2025.
- Over 5 years, Net Margin stood at 10.64% in 2022, then tumbled by 150 bps to 5.28% in 2023, then plunged by 74 bps to 9.17% in 2024, then slumped by 2592 bps to 246.76% in 2025, then jumped by 62 bps to 93.82% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 93.82%, 246.76%, and 40.15% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Vanda Pharmaceuticals | 315.57 Mn | 145.54 Mn | 46.97 Mn | -123.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -123.72% |
| Mar 31, 2026 | -93.82% |
| Dec 31, 2025 | -246.76% |
| Sep 30, 2025 | -40.15% |
| Jun 30, 2025 | -51.70% |
| Mar 31, 2025 | -58.94% |
| Dec 31, 2024 | -9.17% |
| Sep 30, 2024 | -11.21% |
| Jun 30, 2024 | -8.95% |
| Mar 31, 2024 | -8.74% |
| Dec 31, 2023 | -5.28% |
| Sep 30, 2023 | 0.35% |
| Jun 30, 2023 | 3.24% |
| Mar 31, 2023 | 5.16% |
| Dec 31, 2022 | 10.64% |
| Sep 30, 2022 | 4.99% |
| Jun 30, 2022 | 4.02% |
| Mar 31, 2022 | -10.74% |
| Dec 31, 2021 | 10.41% |
| Sep 30, 2021 | 11.02% |